Nitrosamines: Considerations for Marketing Authorisation Holders

2024-01-15T09:49:34+00:00December 19th, 2019|

Nitrosamines: Considerations for Marketing Authorisation Holders Following a press release from the EMA on 26 Sep 2019, all marketing authorisation holders (MAHs) for human medicines containing chemically synthesised active substances must review their products for the possible presence of the carcinogenic class of compounds called nitrosamines. But where [...]